Sort
10,766 grants matching “checkpoint inhibitor”
Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancer
$0Chong-Xian Pan · Va Northern California Health Care Sys · I01 · FY2019 · VA
Epigenetic Regulation of Immune Evasion in Bladder Cancer
$0Joshua James Meeks · Jesse Brown Va Medical Center · I01 · FY2022 · VA
A Novel Drug Target for Aggressive Prostate Cancer
$0Kerry L. Burnstein · Miami Va Health Care System · I01 · FY2024 · VA
Validation of Dihydroorotate Dehydrogenase as a Therapeutic Target in Mesothelioma
$0Mark A. Klein · Minneapolis Va Medical Center · I21 · FY2024 · VA
Defining the role of the EGFR in MHC expression and anti-tumor immune responses.
$0Brian P Pollack · Veterans Health Administration · I01 · FY2015 · VA
Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC
$0Farrah Kheradmand · Michael E Debakey Va Medical Center · I01 · FY2024 · VA
Translational application of mouse models of melanoma brain metastases
$0Suzie Chen · Va New Jersey Health Care System · I01 · FY2022 · VA
A Novel Drug Target for Aggressive Prostate Cancer
$0Kerry L. Burnstein · Miami Va Health Care System · I01 · FY2025 · VA
Oncostatin M Receptor in Pancreatic Adenocarcinoma
$0Teresa A Zimmers · Portland Va Medical Center · I01 · FY2024 · VA
New Approaches to Combat CNS Inflammation: Targeting a Metabolic Enzyme in Demyelinating Disease
$0Brian A. Zabel · Veterans Admin Palo Alto Health Care Sys · I01 · FY2025 · VA
Validation of Dihydroorotate Dehydrogenase as a Therapeutic Target in Mesothelioma
$0Mark A. Klein · Minneapolis Va Medical Center · I21 · FY2025 · VA
Activation of immunosupressive oxidative stress response pathways by tobacco exposure in head and neck cancer
$0Vlad C Sandulache · Michael E Debakey Va Medical Center · I01 · FY2025 · VA
Stratification of Pancreatic Cancer Subpopulations for Effective Immunotherapy
$0Qizhi C. Yao · Michael E Debakey Va Medical Center · I01 · FY2024 · VA
NEW TRANSLATION INITIATION INHIBITORS FOR CANCER THERAPY
$0University Of Arizona · U19 · FY2000 · CA
ANALYSIS OF THE S PHASE CHECKPOINT IN HIGHER EUKARYOTES
$0Child Health And Human Development · Z01 · FY2000 · HD
NEUROTRANSMITTER RECEPTORS IN GLIA
$0Child Health And Human Development · Z01 · FY2000 · HD
The Molecular Mechanism of Cell Cycle Regulation in Budding Yeast
$0Diabetes, Digestive, Kidney Diseases · Z01 · FY2000 · DK
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival
$0Julie A Sterling · Veterans Health Administration · I01 · FY2025 · VA
Targeting NRF2 in Head and Neck Squamous Cell Carcinoma
$0Paul Zolkind · St. Louis Va Medical Center · IK2 · FY2025 · VA
Optimizing Cell Therapy to Counter Adaptive Resistance Mechanisms in Prostate Cancer
$0Avery D. Posey · Philadelphia Va Medical Center · I01 · FY2025 · VA
Antiproliferative Effects Of Small Molecules
$0Dental &Craniofacial Research · Z01 · FY2001 · DE
MTOR AS THERAPEUTIC TARGET IN PEDIATRIC SOLID TUMORS
$0St. Jude Children'S Research Hospital · P01 · FY2002 · CA
Phage Display for Improved Peptide-Based Tumor Targeting and Imaging Agents
$0Charles J Smith · Harry S. Truman Memorial Va Hospital · I01 · FY2023 · VA
MOLECULAR CONTROL OF CELL GROWTH
$0University Of Washington · P50 · FY2002 · DK
Exploring super charged NK cells as a novel cell-based immune therapy in targeting platinum resistant ovarian cancers
$0Sanaz Memarzadeh · Va Greater Los Angeles Healthcare System · I01 · FY2024 · VA